Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells

Full text
Show less -
Freitas, Rosana Aparecida [1] ; Silva dos Santos, Guilherme Augusto [1] ; Gimenes Teixeira, Hamilton Luiz [1] ; Scheucher, Priscila Santos [1] ; Lucena-Araujo, Antonio Roberto [1] ; Gouveia Lima, Ana Silvia [1] ; Abreu e Lima, Rodrigo Siqueira [1] ; Garcia, Aglair Bergamo [1] ; Jordao, Jr., Alceu Afonso [2] ; Faicao, Roberto Passetto [1] ; Vannucchi, Helio [2] ; Rego, Eduardo Magalhaes [1]
Total Authors: 12
[1] Univ Sao Paulo, Div Hematol, Dept Internal Med, Med Sch Ribeirao Preto, BR-14049900 Ribeirao Preto, SP - Brazil
[2] Univ Sao Paulo, Div Nutr, Dept Internal Med, Med Sch Ribeirao Preto, BR-14049900 Ribeirao Preto, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: Leukemia Research; v. 33, n. 7, p. 958-963, JUL 2009.
Web of Science Citations: 6

We analyzed the effect of (+)alpha-tocopheryl succinate (alpha-TOS) alone or associated with arsenic trioxide (ATO) or all-trans retinoid acid (ATRA) in acute promyelocytic leukemia (APL). alpha-TOS-induced apoptosis in APL clinical samples and in ATRA-sensitive (NB4) and ATRA-resistant (NB4-R2) APL cell lines. The effective dose 50% (ED-50) was calculated to be 71 and 58 mu M, for NB4 and NB4-R2, respectively. a-TOS neither induced nor modified ATRA-induced differentiation of APL cells, and did not affect the proliferation and differentiation of normal CD34(+) hematopoietic progenitors in methylcellulose assays. alpha-TOS exerted a moderate antagonistic effect to ATO-induced apoptosis when treatment was done simultaneously but when alpha-TOS was added 24 h after ATO, an additive effect was observed. Our results support the concept of alpha-TOS as an anti-leukemic compound which spares normal hematopoiesis. (C) 2008 Elsevier Ltd. All rights reserved. (AU)

FAPESP's process: 98/14247-6 - Center for Research on Cell-Based Therapy
Grantee:Marco Antonio Zago
Support type: Research Grants - Research, Innovation and Dissemination Centers - RIDC